Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Weight management and incretin-based pharmacotherapy
14 evidence topics · 8 sources
VA/DoD guideline: evidence-based weight management combined with other OSA treatment (weak for)
ATS guideline: comprehensive lifestyle intervention (strong), antiobesity pharmacotherapy evaluation (conditional), and bariatric surgery referral (conditional)
ATS guideline: literature search dates and pharmacotherapies reviewed
ACP guideline: weight loss for all adults with overweight or obesity and OSA (strong recommendation, low-quality evidence)
Tirzepatide label: indication for moderate to severe OSA in adults with obesity
Tirzepatide label: dose escalation and OSA maintenance dosage
Tirzepatide label: design of the OSA trials, AHI of at least 15 and BMI of at least 30
Tirzepatide label: week 52 AHI results in Studies 5 and 6, modified intent-to-treat population, hypopneas scored with 4% oxygen desaturation
| Measure | Study 5 placebo (N = 120) | Study 5 ZEPBOUND MTD (N = 114) | Study 5 difference from placebo (95% CI) | Study 6 placebo (N = 114) | Study 6 ZEPBOUND MTD (N = 119) | Study 6 difference from placebo (95% CI) |
|---|---|---|---|---|---|---|
| AHI change from baseline (events/hr) | “-5.3” | “-25.3” | “-20 (-25.8, -14.2)” | “-5.5” | “-29.3” | “-23.8 (-29.6, -17.9)” |
| Percent change in AHI from baseline | “-3” | “-50.7” | “-47.7 (-65.8, -29.6)” | “-2.5” | “-58.7” | “-56.2 (-73.7, -38.7)” |
| Percent of participants with ≥50% reduction in AHI | “19” | “61.2” | “42.8 (30.8, 54.8)” | “23.3” | “72.4” | “48.6 (36.6, 60.7)” |
| Percent with AHI <5 or AHI 5-14 and ESS ≤10 | “15.9” | “42.2” | “28.7 (18.3, 39.2)” | “14.3” | “50.2” | “33.2 (22.1, 44.3)” |
“Data from polysomnographic studies were scored centrally with the use of the American Academy of Sleep Medicine rule 1B for identification of hypopneas (which specifies a ≥30% reduction in airflow for ≥10 seconds and oxygen desaturation of ≥4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SURMOUNT-OSA: AHI change at week 52, treatment-regimen estimand, hypopneas scored with 4% oxygen desaturation
“In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All results are reported with the use of the treatment-regimen estimand unless otherwise specified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 82.9% of the participants completed the trial (91.5% in the tirzepatide groups and 74.4% in the placebo groups) and 79.7% adhered to the assigned regimen (87.6% in the tirzepatide groups and 71.9% in the placebo groups) (Fig. S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SURMOUNT-OSA: AHI change at week 52, efficacy estimand
“For the efficacy estimand, the change in AHI at week 52 was −27.4 events per hour (95% CI, −31.6 to −23.2) with tirzepatide and −4.8 events per hour (95% CI, −9.3 to −0.3) with placebo, for an estimated treatment difference of −22.5 events per hour (95% CI, −28.7 to −16.4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the efficacy estimand, the change in AHI at week 52 with tirzepatide was −30.4 events per hour (95% CI, −34.3 to −26.5) with tirzepatide and −6.0 events per hour (95% CI, −10.3 to −1.6) with placebo, for an estimated treatment difference of −24.4 events per hour (95% CI, −30.3 to −18.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SURMOUNT-OSA: percent change in body weight at week 52, treatment-regimen estimand
| Measure | Trial 1 tirzepatide | Trial 1 placebo | Trial 1 difference | Trial 2 tirzepatide | Trial 2 placebo | Trial 2 difference |
|---|---|---|---|---|---|---|
| Percent change in body weight (95% CI) | “−17.7 (−19.0 to −16.3)”View highlighted excerpt for this quote | “−1.6 (−2.9 to −0.2)”View highlighted excerpt for this quote | “−16.1 (−18.0 to −14.2)”View highlighted excerpt for this quote | “−19.6 (−21.0 to −18.2)”View highlighted excerpt for this quote | “−2.3 (−3.8 to −0.9)”View highlighted excerpt for this quote | “−17.3 (−19.3 to −15.3)”View highlighted excerpt for this quote |
AASM provider fact sheet: tirzepatide as part of comprehensive OSA care
AASM guideline: discussion of bariatric surgery referral for adults with BMI of at least 35 who are intolerant or unaccepting of PAP (strong)
“Recommendation 2: We recommend that clinicians discuss referral to a bariatric surgeon with adults with OSA and obesity (class II/III, BMI ≥ 35) who are intolerant or unaccepting of PAP as part of a patient-oriented discussion of alternative treatment options (STRONG).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TF made a strong recommendation in favor of bariatric surgery referral based on moderate-quality evidence from 2 RCTs and 28 observational studies that showed clinically meaningful improvements in several critical outcomes, and the benefits of discussing referral over the harms of no treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, iron malabsorption, gastric ulcer, vitamin deficiency, bowel obstruction or leak, gastrointestinal reflux disorder, and gastric band slippage have been reported but the incidence of these is low.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ERS guideline: bariatric surgery evaluation after an unsuccessful weight reduction programme (conditional recommendation, very low quality of evidence), AHI scoring rule not stated
“In adult obese patients with OSA, we suggest bariatric surgery evaluation versus weight-reducing diet when weight has not improved despite participating in a comprehensive weight reduction programme and if there are no contraindications (conditional recommendation, very low quality of evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The difference between the change scores was −11.5 events·h−1 (95% CI −28.3–5.3 events·h−1), which was not statistically significant (p=0.18).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote